(MedPage Today) -- BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS) in patients with prostate cancer at high risk for biochemical recurrence, according to…
A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 patients worldwide and was led by Cedars…
A groundbreaking study reveals that cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy lived dramatically longer than those who didn’t. Researchers from the University of Florida and MD Anderson…
The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor activity, particularly in patients with refractory mesothelioma, according to results from a trial led by researchers…
The Medicaid Cancer Foundation (MCF) has unveiled its 2025 Cancer Awareness Campaign in Abuja, marking 11 years of sustained efforts in cancer prevention, diagnosis, and patient support across Nigeria.
Patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine, researchers have found.
An estimated 74.7% of patients treated with the combination were event-free at two years, compared to 39.4% who received surgery only, the companies said
Researchers found that triple-negative breast cancer cells are “addicted” to lipids, a feature tied to obesity. By studying mice, they discovered that high lipid levels alone accelerate tumor growth. Lowering these fats slowed cancer…
Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation…
Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma (ccRCC) – a type of kidney…
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents-antibody-drug conjugates (ADCs)-can dramatically improve outcomes for patients with early-stage HER2…
Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation…
SAN FRANCISCO, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted…
A cancer patient has vowed to “put smiles on children’s faces” with the support of his Wolverhampton football club by organising a toy appeal for youngsters in a city hospital.
(MedPage Today) -- BERLIN -- In a global phase III trial, the addition of durvalumab (Imfinzi) to standard chemotherapy given before and after surgery led to a statistically significant and "clinically meaningful" survival improvement in…